185 related articles for article (PubMed ID: 24952635)
1. Thioridazine inhibits angiogenesis and tumor growth by targeting the VEGFR-2/PI3K/mTOR pathway in ovarian cancer xenografts.
Park MS; Dong SM; Kim BR; Seo SH; Kang S; Lee EJ; Lee SH; Rho SB
Oncotarget; 2014 Jul; 5(13):4929-34. PubMed ID: 24952635
[TBL] [Abstract][Full Text] [Related]
2. The antihypertension drug doxazosin inhibits tumor growth and angiogenesis by decreasing VEGFR-2/Akt/mTOR signaling and VEGF and HIF-1α expression.
Park MS; Kim BR; Dong SM; Lee SH; Kim DY; Rho SB
Oncotarget; 2014 Jul; 5(13):4935-44. PubMed ID: 24952732
[TBL] [Abstract][Full Text] [Related]
3. sMEK1 inhibits endothelial cell proliferation by attenuating VEGFR-2-dependent-Akt/eNOS/HIF-1α signaling pathways.
Kim BR; Seo SH; Park MS; Lee SH; Kwon Y; Rho SB
Oncotarget; 2015 Oct; 6(31):31830-43. PubMed ID: 26378810
[TBL] [Abstract][Full Text] [Related]
4. Anti-angiogenic effects of thioridazine involving the FAK-mTOR pathway.
Byun HJ; Lee JH; Kim BR; Kang S; Dong SM; Park MS; Lee SH; Park SH; Rho SB
Microvasc Res; 2012 Nov; 84(3):227-34. PubMed ID: 23022044
[TBL] [Abstract][Full Text] [Related]
5. SB365 inhibits angiogenesis and induces apoptosis of hepatocellular carcinoma through modulation of PI3K/Akt/mTOR signaling pathway.
Hong SW; Jung KH; Lee HS; Choi MJ; Son MK; Zheng HM; Hong SS
Cancer Sci; 2012 Nov; 103(11):1929-37. PubMed ID: 22909393
[TBL] [Abstract][Full Text] [Related]
6. GABARBP down-regulates HIF-1α expression through the VEGFR-2 and PI3K/mTOR/4E-BP1 pathways.
Park SH; Kim BR; Lee JH; Park ST; Lee SH; Dong SM; Rho SB
Cell Signal; 2014 Jul; 26(7):1506-13. PubMed ID: 24686084
[TBL] [Abstract][Full Text] [Related]
7. Tanshinone I attenuates the malignant biological properties of ovarian cancer by inducing apoptosis and autophagy via the inactivation of PI3K/AKT/mTOR pathway.
Zhou J; Jiang YY; Chen H; Wu YC; Zhang L
Cell Prolif; 2020 Feb; 53(2):e12739. PubMed ID: 31820522
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423.
Kashiyama T; Oda K; Ikeda Y; Shiose Y; Hirota Y; Inaba K; Makii C; Kurikawa R; Miyasaka A; Koso T; Fukuda T; Tanikawa M; Shoji K; Sone K; Arimoto T; Wada-Hiraike O; Kawana K; Nakagawa S; Matsuda K; McCormick F; Aburatani H; Yano T; Osuga Y; Fujii T
PLoS One; 2014; 9(2):e87220. PubMed ID: 24504419
[TBL] [Abstract][Full Text] [Related]
9. Thioridazine induces apoptosis by targeting the PI3K/Akt/mTOR pathway in cervical and endometrial cancer cells.
Kang S; Dong SM; Kim BR; Park MS; Trink B; Byun HJ; Rho SB
Apoptosis; 2012 Sep; 17(9):989-97. PubMed ID: 22460505
[TBL] [Abstract][Full Text] [Related]
10. FAM83D inhibits autophagy and promotes proliferation and invasion of ovarian cancer cells via PI3K/AKT/mTOR pathway.
Zhu H; Diao S; Lim V; Hu L; Hu J
Acta Biochim Biophys Sin (Shanghai); 2019 May; 51(5):509-516. PubMed ID: 30939187
[TBL] [Abstract][Full Text] [Related]
11. Programmed cell death 6 (PDCD6) inhibits angiogenesis through PI3K/mTOR/p70S6K pathway by interacting of VEGFR-2.
Rho SB; Song YJ; Lim MC; Lee SH; Kim BR; Park SY
Cell Signal; 2012 Jan; 24(1):131-9. PubMed ID: 21893193
[TBL] [Abstract][Full Text] [Related]
12. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
[TBL] [Abstract][Full Text] [Related]
13. Thioridazine Sensitizes Esophageal Carcinoma Cell Lines to Radiotherapy-Induced Apoptosis In Vitro and In Vivo.
Li H; Juan L; Xia L; Wang Y; Bao Y; Sun G
Med Sci Monit; 2016 Jul; 22():2624-34. PubMed ID: 27453171
[TBL] [Abstract][Full Text] [Related]
14. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.
Sheppard KE; Cullinane C; Hannan KM; Wall M; Chan J; Barber F; Foo J; Cameron D; Neilsen A; Ng P; Ellul J; Kleinschmidt M; Kinross KM; Bowtell DD; Christensen JG; Hicks RJ; Johnstone RW; McArthur GA; Hannan RD; Phillips WA; Pearson RB
Eur J Cancer; 2013 Dec; 49(18):3936-44. PubMed ID: 24011934
[TBL] [Abstract][Full Text] [Related]
15. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
Choi HJ; Heo JH; Park JY; Jeong JY; Cho HJ; Park KS; Kim SH; Moon YW; Kim JS; An HJ
Gynecol Oncol; 2019 Apr; 153(1):135-148. PubMed ID: 30686552
[TBL] [Abstract][Full Text] [Related]
16. Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells.
Peng Y; Li L; Huang M; Duan C; Zhang L; Chen J
Cell Signal; 2014 Dec; 26(12):2782-92. PubMed ID: 25193113
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Prostate Cancer DU-145 Cells Proliferation by
Li X; Tang Y; Yu F; Sun Y; Huang F; Chen Y; Yang Z; Ding G
Mar Drugs; 2018 Sep; 16(9):. PubMed ID: 30208576
[TBL] [Abstract][Full Text] [Related]
18. MARCKSL1 exhibits anti-angiogenic effects through suppression of VEGFR-2-dependent Akt/PDK-1/mTOR phosphorylation.
Kim BR; Lee SH; Park MS; Seo SH; Park YM; Kwon YJ; Rho SB
Oncol Rep; 2016 Feb; 35(2):1041-8. PubMed ID: 26555156
[TBL] [Abstract][Full Text] [Related]
19. The anti-tumor activator sMEK1 and paclitaxel additively decrease expression of HIF-1α and VEGF via mTORC1-S6K/4E-BP-dependent signaling pathways.
Kim BR; Yoon K; Byun HJ; Seo SH; Lee SH; Rho SB
Oncotarget; 2014 Aug; 5(15):6540-51. PubMed ID: 25153728
[TBL] [Abstract][Full Text] [Related]
20. SKLB-M8 induces apoptosis through the AKT/mTOR signaling pathway in melanoma models and inhibits angiogenesis with decrease of ERK1/2 phosphorylation.
Wang J; Yang Z; Wen J; Ma F; Wang F; Yu K; Tang M; Wu W; Dong Y; Cheng X; Nie C; Chen L
J Pharmacol Sci; 2014; 126(3):198-207. PubMed ID: 25341684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
